SCHEMBL62749

SCHEMBL62749

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2cccnc2)c(O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 4/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
TLR2 O60603 1/20 0.39
HTT P42858 2/20 0.39
CALCA P06881 1/20 0.39
EGLN1 Q9GZT9 1/20 0.36
KCNH2 Q12809 1/20 0.36
ABCB1 P08183 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PKM P14618 1/20 0.36
CYP17A1 P05093 1/20 0.36
CYP19A1 P11511 1/20 0.36
HSD11B1 P28845 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL53142 0.91 CYP2C9 (0.45) CYP2C9GAAKDM4EALDH1A1KMT2A
SCHEMBL64543 0.91 CYP2C9 (0.45) CYP2C9LMNAKDM4EALDH1A1ALOX12
SCHEMBL64597 0.88 CYP2C9 (0.47) CYP2C9KCNH2
SCHEMBL63518 0.87 CYP2C9 (0.46) CYP2C9GAALMNAKDM4EALDH1A1
SCHEMBL63541 0.87 CYP2C9 (0.40) CYP2C9LMNAALDH1A1KMT2AMEN1
SCHEMBL62751 0.87 CYP2C9 (0.47) CYP2C9LMNAALDH1A1KMT2AMEN1
SCHEMBL63545 0.87 CYP2C9 (0.46) CYP2C9KCNH2
SCHEMBL63919 0.87 CYP2C9 (0.46) CYP2C9LMNAALDH1A1KMT2AMEN1
SCHEMBL63538 0.87 CYP2C9 (0.46) CYP2C9GAALMNAKDM4EALDH1A1
SCHEMBL52664 0.87 CYP2C9 (0.55) CYP2C9GAALMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885GAA 195/4885LMNA 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.